Novartis was in a phase 2 for healthy and Cystic Fibrosis patients since 2014, and in February terminated the trial prior to completion, and readout. The link is NCT02190604. QBW251 was one of a few potentiators that are being tested for efficacy. Perhaps Novartis may see some value in potentiator CTP-656, once the company completes their phase 2 clinical trial sometime in 2017. Thank you for reading.
Do we know why it was terminated?
ReplyDeleteHi LittleB21
ReplyDeleteWe have not found information for that. There was no mention from Novartis. There was however, a presentation regarding that potentiator below, but I was not able to get the transcripts for that presentation.
39th European Cystic Fibrosis Conference,
08 - 11 June 2016,
Basel, Switzerland
Scientific Programme
mRNA replacement therapy 08:52 - 09:14
Isabelle Sermet (Paris, France)
Novartis potentiator preclinical to clinical 09:14 - 09:29
Shamsah Kazani (Cambridge, United States)